AIM： To investigate choroidal thickness changes in the horizontal meridian after orthokeratology. METHODS： This is a prospective cross-sectional observed study. Subjects （n=30; 11.3±1.7y） with low-to-moderate...AIM： To investigate choroidal thickness changes in the horizontal meridian after orthokeratology. METHODS： This is a prospective cross-sectional observed study. Subjects （n=30; 11.3±1.7y） with low-to-moderate myopia （-1.0 to -6.0 diopters）, wore orthokeratology （Ortho-K） lenses for 3mo. Before and after Ortho-K, OCT scans were made through the fovea in the horizontal meridian. Choroid thickness around the fovea was acquired by custom software. The analyzed regions along the horizontal meridian were divided into 7 equal zones. Ocular parameters were measured by Lenstar LS 900 non-contact biometry. RESULTS： Only the right eye ocular parameters were analyzed in this study. Before Ortho-K, choroidal thickness along the horizontal meridian was 273.7±31.8 μm in the temporal zone, 253.1±38.6 μm in the macula zone, and 194.8±52.2 μm in the nasal zone. After Ortho-K, the choroid was thicker in each horizontal zone （P〈0.05）. The increased thickness was greatest in the temporal zone （13.5±22.5 μm） and least in the nasal zone （8.4±14.2 μm）. The axial length （AL） increased 0.02 mm （P〉0.05）. The choroid thickness change in each horizontal zone was negatively correlated with AL （r, -0.3 to -0.4; P〈0.05） except one of the nasal zones. CONCLUSION： In myopic children, the thickness of the choroid is greatest in the temporal zone and thinnest in the nasal zone. After nightly Ortho-K for 3mo, the thickness increase along the horizontal meridian. The choroid thickness changes are negatively correlated with the change of AL.展开更多
Danshen-Chuanxiongqin Injection(DCI)is a commonly used traditional Chinese medicine for the treatment of cerebral ischemic stroke in China.However,its underlying mechanisms remain completely understood.The current stu...Danshen-Chuanxiongqin Injection(DCI)is a commonly used traditional Chinese medicine for the treatment of cerebral ischemic stroke in China.However,its underlying mechanisms remain completely understood.The current study was designed to explore the protective mechanisms of DCI against cerebral ischemic stroke through integrating whole-transcriptome sequencing coupled with network pharmacology analysis.First,using a mouse model of cerebral ischemic stroke by transient middle cerebral artery occlusion(tMCAO),we found that DCI(4.10 mL·kg−1)significantly alleviated cerebral ischemic infarction,neurological deficits,and the pathological injury of hippocampal and cortical neurons in mice.Next,the whole-transcriptome sequencing was performed on brain tissues.The cerebral ischemia disease(CID)network was constructed by integrating transcriptome sequencing data and cerebrovascular disease-related genes.The results showed CID network was imbalanced due to tMCAO,but a recovery regulation was observed after DCI treatment.Pathway analysis of the key genes with recovery efficiency showed that the neuroinflammation signaling pathway was highly enriched,while the TLR2/TLR4-MyD88-NF-κB pathway was predicted to be affected.Consistently,the in vivo validation experiments confirmed that DCI exhibited protective effects against cerebral ischemic stroke by inhibiting neuroinflammation via the TLR2/TLR4-MyD88-NF-κB pathway.More interestingly,DCI markedly suppressed the neutrophils infiltrated into the brain parenchyma via the choroid plexus route and showed anti-neuroinflammation effects.In conclusion,our results provide dependable evidence that inhibiting neuroinflammation via the TLR2/TLR4-MyD88-NF-κB pathway is the main mechanism of DCI against cerebral ischemic stroke in mice.展开更多
视网膜和脉络膜新生血管可引发玻璃体出血、视网膜下出血、牵引性视网膜脱离等,从而危害患眼视力。这类病变常见于老年性黄斑变性(age related macular degeneration,AMD)、糖尿病视网膜病变(diabetic retinopathy,DR)、视网膜静脉阻塞(...视网膜和脉络膜新生血管可引发玻璃体出血、视网膜下出血、牵引性视网膜脱离等,从而危害患眼视力。这类病变常见于老年性黄斑变性(age related macular degeneration,AMD)、糖尿病视网膜病变(diabetic retinopathy,DR)、视网膜静脉阻塞(retinal vein occlusions,RVO)、早产儿视网膜病变(retinopathy of prematurity,ROP)等眼底病。当前,药物治疗新生血管(neovscularization,NV)主要是针对NV生成的不同阶段抑制其生长。本文综述了目前已用于临床及正在进行临床试验的治疗眼底新生血管的药物。展开更多
基金Supported by National Health and Family Planning Commission of the People’s Republic of China(No.201302015)Zhejiang Provincial Natural Science Foundation of China(No.LY14H120007)+1 种基金Wenzhou Commonweal Technology Project(No.Y20150253)Eye Hospital of Wenzhou Medical University Innovation Grant(No.YNCX201402)
文摘AIM： To investigate choroidal thickness changes in the horizontal meridian after orthokeratology. METHODS： This is a prospective cross-sectional observed study. Subjects （n=30; 11.3±1.7y） with low-to-moderate myopia （-1.0 to -6.0 diopters）, wore orthokeratology （Ortho-K） lenses for 3mo. Before and after Ortho-K, OCT scans were made through the fovea in the horizontal meridian. Choroid thickness around the fovea was acquired by custom software. The analyzed regions along the horizontal meridian were divided into 7 equal zones. Ocular parameters were measured by Lenstar LS 900 non-contact biometry. RESULTS： Only the right eye ocular parameters were analyzed in this study. Before Ortho-K, choroidal thickness along the horizontal meridian was 273.7±31.8 μm in the temporal zone, 253.1±38.6 μm in the macula zone, and 194.8±52.2 μm in the nasal zone. After Ortho-K, the choroid was thicker in each horizontal zone （P〈0.05）. The increased thickness was greatest in the temporal zone （13.5±22.5 μm） and least in the nasal zone （8.4±14.2 μm）. The axial length （AL） increased 0.02 mm （P〉0.05）. The choroid thickness change in each horizontal zone was negatively correlated with AL （r, -0.3 to -0.4; P〈0.05） except one of the nasal zones. CONCLUSION： In myopic children, the thickness of the choroid is greatest in the temporal zone and thinnest in the nasal zone. After nightly Ortho-K for 3mo, the thickness increase along the horizontal meridian. The choroid thickness changes are negatively correlated with the change of AL.
基金supported by the National S&T Major Project(No.2018ZX09201011)the National Youth Topnotch Talent Support Program(No.W02070098).
文摘Danshen-Chuanxiongqin Injection(DCI)is a commonly used traditional Chinese medicine for the treatment of cerebral ischemic stroke in China.However,its underlying mechanisms remain completely understood.The current study was designed to explore the protective mechanisms of DCI against cerebral ischemic stroke through integrating whole-transcriptome sequencing coupled with network pharmacology analysis.First,using a mouse model of cerebral ischemic stroke by transient middle cerebral artery occlusion(tMCAO),we found that DCI(4.10 mL·kg−1)significantly alleviated cerebral ischemic infarction,neurological deficits,and the pathological injury of hippocampal and cortical neurons in mice.Next,the whole-transcriptome sequencing was performed on brain tissues.The cerebral ischemia disease(CID)network was constructed by integrating transcriptome sequencing data and cerebrovascular disease-related genes.The results showed CID network was imbalanced due to tMCAO,but a recovery regulation was observed after DCI treatment.Pathway analysis of the key genes with recovery efficiency showed that the neuroinflammation signaling pathway was highly enriched,while the TLR2/TLR4-MyD88-NF-κB pathway was predicted to be affected.Consistently,the in vivo validation experiments confirmed that DCI exhibited protective effects against cerebral ischemic stroke by inhibiting neuroinflammation via the TLR2/TLR4-MyD88-NF-κB pathway.More interestingly,DCI markedly suppressed the neutrophils infiltrated into the brain parenchyma via the choroid plexus route and showed anti-neuroinflammation effects.In conclusion,our results provide dependable evidence that inhibiting neuroinflammation via the TLR2/TLR4-MyD88-NF-κB pathway is the main mechanism of DCI against cerebral ischemic stroke in mice.
文摘视网膜和脉络膜新生血管可引发玻璃体出血、视网膜下出血、牵引性视网膜脱离等,从而危害患眼视力。这类病变常见于老年性黄斑变性(age related macular degeneration,AMD)、糖尿病视网膜病变(diabetic retinopathy,DR)、视网膜静脉阻塞(retinal vein occlusions,RVO)、早产儿视网膜病变(retinopathy of prematurity,ROP)等眼底病。当前,药物治疗新生血管(neovscularization,NV)主要是针对NV生成的不同阶段抑制其生长。本文综述了目前已用于临床及正在进行临床试验的治疗眼底新生血管的药物。
